MEDICENNA: CLINICAL TRIALS OVERVIEW
Medicenna recognizes that patient participation in clinical trials is critical in order to advance treatment for cancer and is developing its lead product, MDNA55, for cancers that have a significant unmet medical need.
MDNA55 is currently being studied in clinical trials for treatment of CNS cancers.
Phase 2 Clinical Trial Open To Enrollment
In December of 2016, Medicenna announced the initiation of its Phase 2 trial of MDNA55 in adults with recurrent Glioblastoma where MDNA55 is administered intratumorally using one infusion.
Hospitals Participating in this clinical trial include:
- University of California San Francisco – San Francisco, California, United States, 94143 Recruiting
- Contact: Nurse Line 415-353-2652
- Principal Investigator: Nicholas Butowski, MD
- John Wayne Cancer Institute at Providence Saint John’s Health Center, Santa Monica, California, United States, 90404 Recruiting
- Marcus Neuroscience Institute at Boca Raton Regional Hospital, Boca Raton, Florida, United States, 33486 Not Yet Recruiting
- New York
- Weill Cornell – New York Presbyterian Hospital, New York, New York, United States, 10022 Not Yet Recruiting
- North Carolina
- Duke University Medical Center, Durham, North Carolina, United States, 27710 Recruiting
- Contact: Brain Tumor Center - Phone: 919-684-5301
- Principal Investigator: Dina Randazzo, MD
- Cleveland Clinic, Cleveland, Ohio, United States, 44195 Recruiting
- Ohio State University, Columbus, Ohio, United States, 43210 Recruiting
- University of Texas Southwestern Cancer Center, Dallas, Texas, United States, 75390
- Cancer Therapy and Research Center At The University of Texas Health Science Center
At San Antonio, San Antonio, Texas, United States, 78229 Recruiting
For more information about this study, including study design, eligibility criteria and up to date contact information for the participating hospitals please visit trial record (NCT02858895) on clinicaltrials.gov.
Find Open Clinical Trials
Search clinicaltrials.gov to find out if other clinical trials exist for a specific medicine for a particular disease.